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Objective: To describe the relationship between type 2 diabetes and all-cause mortality amongst 
adults with COVID-19 in the critical care setting. 
Research Design and Methods: Nationwide retrospective cohort study in people admitted to 
hospital in England with COVID-19 requiring admission to a high dependency unit (HDU) or 
intensive care unit (ICU) between March 1, 2020 and July 27, 2020. Cox proportional hazards 
models were used to estimate 30 day in-hospital all-cause mortality associated with type 2 diabetes, 
adjusted for age, sex, ethnicity, obesity, and other major comorbidities (chronic respiratory disease, 
asthma, chronic heart disease, hypertension, immunosuppression, chronic neurological disease, 
chronic renal disease, and chronic liver disease). 
Results: 19,256 COVID-19 related HDU and ICU admissions were included in the primary 
analysis, including 13,809 HDU (mean age 70), and 5,447 ICU admissions (mean age 58). 3,524 
(18.3%) had type 2 diabetes. 5,077 people (26.4%) died during the study period. People with type 2 
diabetes were at increased risk of death (adjusted hazard ratio (aHR) 1.23 [95%CI 1.14;1.32]), 
results were consistent in HDU and ICU subsets. The relative mortality risk associated with type 2 
diabetes decreased with increasing age (age 18-49 aHR 1.50 [95%CI 1.05;2.15]; age 50-64 1.29 
[1.10;1.51]; age 65 or greater 1.18 [1.09;1.29], p-value for age:type 2 diabetes interaction 0.002). 
Conclusions: Type 2 diabetes may be an independent prognostic factor for survival in people with 
severe COVID-19 requiring critical care treatment, and in this setting the risk increase associated 
with type 2 diabetes is greatest in younger people.  
Introduction 
In early 2020, coronavirus disease 2019 (COVID-19), caused by the new highly-infectious 
organism now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2), was 
formally declared a pandemic by the World Health Organisation.(1) With a global prevalence of 
9.3%,(2) it is unsurprising that diabetes is one of the most common comorbidities seen in people with 
COVID-19, second only to hypertension.(3) People with type 2 diabetes are known to be not only 
more susceptible to infections in general,(4) but also require hospitalization more often,(5) resulting 
in an overall worse prognosis.(6) As the COVID-19 pandemic has progressed, a similar pattern of a 
worse prognosis for people with diabetes who contract COVID-19 has been reported in population-
based studies,(7, 8) with an increased risk of intensive care admission,(9-11) and worse mortality 
outcome in some but not all hospital cohorts.(12-14)  
 
 For people admitted to intensive care, studies published early in the course of the global 
pandemic suggested diabetes is an important prognostic factor even in severe COVID-19 (New York 
n=373, 40.2% with diabetes; unadjusted odds ratio (OR) for mortality in those with diabetes 2.31 
[95%CI 1.34, 4.00]; Wuhan, China, n= 193, 24.9% with diabetes; adjusted hazard ratio 1.53 [95%CI 
1.02, 2.30]).(11, 15) Two larger, more recent critical care studies have reported smaller effect sizes 
(Italy, n=3988, 12.9% with diabetes; adjusted OR 1.18 [95%CI 1.01, 1.39]; USA, n=2,215, 38.9% 
with diabetes; adjusted OR 1.14 [95%CI 0.91, 1.43]).(16, 17) Heterogeneity across these studies 
likely reflects a combination of local variation in prevalence of diabetes, variation in the 
characteristics of people with diabetes, and the limited geo-temporal snapshots each study represents. 
Data on the additional mortality associated with diabetes in critical care across the entire first wave 
of COVID-19 are lacking in these studies, and potential heterogeneity in the risk associated with 
diabetes by age and other clinical features has yet to be fully explored. 
 
We aimed to establish the clinical utility of type 2 diabetes as a prognostic factor for survival 
in people admitted to critical care with COVID-19, using national data over the course of the entire 




















Data were accessed from the COVID-19 Hospitalisation in England Surveillance System 
(CHESS), established by Public Health England.(18) Reporting to CHESS is daily via web tool and 
is mandatory for hospitals in England. The data specification comprises epidemiological information 
for people with proven or a high likelihood of COVID-19 requiring hospitalisation and high 
dependency unit (HDU) or intensive care unit (ICU) management, including demographics, 
comorbidities including diabetes and obesity, and outcome. Confirmation of infection was by reverse 
transcriptase polymerase chain reaction (PCR) of nasopharyngeal and/or oropharyngeal swabs as it 
was the only available method during the study period. National testing policy changed throughout 
the study period, however, all people with a suspicion of COVID-19 and who were admitted to 
hospital were tested,(19) and people were potentially re-tested multiple times if the initial results were 
negative but clinical suspicion remained high. At the time of data extraction (27th July, 2020), data 
on 23,935 cases across 108 hospitals had been submitted to CHESS. 
 
Study population 
Inclusion and Exclusion Criteria 
The study population comprised people in CHESS aged 18-99 inclusive who required HDU 
or ICU admission with confirmed or clinically diagnosed COVID-19 (91.4% were PCR swab positive 
result at some point in their admission) from 1st March 2020 to 27th July 2020 inclusive, and were 
not pregnant (n=22,082). Pregnancy is associated with altered metabolic physiology; due to the 
limited information about this group, an a priori decision was made to exclude them from the analysis.  
Cohorts 
The primary cohort for analysis was all patients admitted to either HDU or ICU at any point 
during the study period (HDU/ICU cohort). We separately examined the subsets of all patients 
admitted to HDU but not ICU during the study period (HDU cohort), and all patients admitted to ICU 
during the study period (ICU cohort). People with type 1 diabetes were excluded from these primary 
cohorts and are analysed separately. 
 
Recorded clinical features  
Available clinical features comprised demographic characteristics (age, sex, ethnicity), 
obesity status, and comorbidities, as defined in the CHESS data specification,(18) recorded during 
critical care admission. We grouped ethnicity into major UK ethnic census groups: white, black, 
Asian, mixed, other, or not recorded. We defined obesity as non-obese (BMI<30), obese 
(BMI≥30), or not recorded, as derived from recorded BMI category (coded in CHESS as <18.5, 
18.5-24.9, 25-29.9, 30-39.9, >39.9, No, Missing or Unknown) where available or recorded clinical 
obesity (coded as No, Borderline, Yes, Missing or Unknown) if BMI was not available. Coded 
comorbidities were diabetes (separated by type 1 and 2), chronic respiratory disease; asthma 
requiring medication; chronic/congenital heart disease; hypertension; immunosuppression (due to 
disease or treatment); chronic neurological disease; chronic renal disease; and chronic liver disease, 
all coded as No, Yes, Missing or Unknown.  
 
Missing Data 
We found variation in reporting of information on comorbidity at hospital level, with a limited 
number of hospitals reporting very little information on comorbidity. For our primary analysis we 
excluded all patients from 15 hospitals where comorbidity recording was missing for over 50% of 
people (n=2,151; sFlowchart 1). After filtering the CHESS cohort by missingness, we defined binary 
variables for each comorbidity (Yes versus No/Missing/Unknown), assuming that, in this mostly 
complete subset, missing or unknown coded data represented the absence of that condition. We tested 
the validity of this assumption in the sensitivity analysis described later. 
 
Outcome 
The outcome was in-hospital all-cause mortality. People were followed up from admission to 
hospital until the earliest of: death, hospital transfer, date of last follow-up in CHESS, or a length of 
stay of 30 days. To account for discharge from hospital as a competing risk, people who were 
discharged were assumed no longer at risk of death and so were not censored at the day of discharge 
and instead had their follow-up time set to 30 days.(12) 
 
Statistical Analysis  
Primary analysis  
Recorded clinical features were described, overall and by recorded type 2 diabetes status. We 
estimated the risk of 30-day mortality for each cohort by type 2 diabetes status using survival analysis 
with days at risk as the timescale. 30-day mortality covered 98% of the deaths observed over the 
maximum cohort follow-up. Kaplan-Meier survival functions and Cox proportional hazards models 
were used to evaluate the association between type 2 diabetes and mortality, with proportional 
hazards assumptions tested through examination of the schoenfeld residuals. All models included 
type 2 diabetes status, and were sequentially increased in complexity with adjustment firstly for age 
(with exploration of age as linear, category, and as a 3-knot non-linear restricted cubic spline), before 
adding sex, ethnicity, obesity, and comorbidities. The primary, fully adjusted, model comprised all 
these features. For the ICU cohort, we started follow up on the date of ICU admission, and adjusted 
for days from hospitalisation to ICU admission.  
 
Subgroup analysis 
Analysis of the primary outcome for the HDU/ICU cohort was repeated in subgroups 
defined by major clinical characteristics; age (18-49, 50-64, 65+), sex, ethnicity, by the presence or 
absence of obesity, and by the presence or absence of at least one other comorbidity. To explore 
temporal trends, subgroups were defined by calendar month of hospital admission (March, April, 
May-July, 2020).  
 
Sensitivity analysis 
To explore the sensitivity to the decision to filter patients by degree of missing comorbidity 
data at hospital level, we described recorded characteristics of patients in included and excluded 
hospitals, and assessed whether the mortality associated with type 2 diabetes differed in included and 
excluded hospitals. To explore sensitivity of our findings to potential temporal changes in mortality 
over the study period, calendar week of hospital admission was included as an additional linear 
continuous covariate in multivariable analysis. 
 
We conducted a propensity score matched analysis to evaluate whether the presence of type 
2 diabetes increased the risk of death compared with people with the same clinical characteristics but 
without type 2 diabetes. The full set of recorded clinical features previously described were 
considered potential confounders and used for matching. Missing information for ethnicity and 
obesity were coded as missing categories, providing a full patient set.(20) Pairs were matched without 
replacement on the logit of the propensity score, and a caliper size of 0.05 was applied for all matched 
pairs. Separate propensity-score models were fitted for each cohort. Cox proportional models were 
stratified by matched set to account for the matched nature of the propensity score defined cohorts. 
 
We repeated the primary analysis with the following changes to formally assess the impact of 
the assumptions made: 1) excluding transferred patients and patients who remained in hospital; 2) 
including only patients with PCR swab positive results during admission; 3) including only hospitals 
with at least 75% complete comorbidity data; 4) including all patients in all hospitals and assuming 
Missing/Unknown represented the absence of a comorbidity; 5) extending the Cox proportional 
hazards model to incorporate hospital level random effects to account for within-hospital 
homogeneity in outcomes (frailty model with a random effect per hospital trust);(21) 6) to check the 
validity of our approach by accounting for discharge as a competing risk we used a Fine & Gray 
model. 
 
Evaluation of missing data 
To evaluate the appropriateness of equating diabetes status coded as missing in CHESS to the 
absence of diabetes, we used multiple imputation by chain equations (5 imputations) to fill missing 
values for diabetes status and all other missing values for ethnicity, obesity, and other comorbidities. 
This approach assumes missing values are missing at random.(22) We then repeated the full 
multivariable analysis for each cohort using the imputation model, to determine whether this model 
gave different results to our primary analysis. 
 
COVID-19 mortality risk in people with Type 1 diabetes 
Mortality in people with recorded type 1 diabetes was compared to people with type 2 
diabetes using adjusted Cox regression, as described above. A propensity matched analysis was also 
utilised, as previously described, to compare the mortality risk for people with type 1 diabetes to 
similar patients without type 1 diabetes. Analyses was limited to the combined HDU/ICU cohort 




Analyses were conducted with R (version 3.6.2),(25) including use of the packages survival, 





19,256 patients were included in the primary cohort admitted to HDU (n=13,809) or ICU 
(n=5,447) [sFlowchart 1 and sTable 1]. Mean age was 67, 60.1% of patients were male, 27.0% of 
patients were of non-white ethnicity, and 18.3% had type 2 diabetes. sTable 1 shows the overall 
characteristics of patients in the separate HDU and ICU cohorts. ICU patients were younger, and 
more commonly male and of non-white ethnicity (mean age 58, 70.6% male, 37.1% non-white) 
than HDU only admitted patients (mean age 70, 55.9% male, 23.1% non-white). 
 
In the primary HDU/ICU cohort, people with type 2 diabetes (n=3,524, 18.3%) were of 
similar age to those without type 2 diabetes (mean 67 verses 66), and were more commonly 
recorded as being of non-white ethnicity (41.5% versus 23.5%) and obese (45.1% versus 31.4%) 
(Table 1). All comorbidities were more common in people with type 2 diabetes. 
 
Type 2 diabetes is an independent prognostic factor for mortality in severe COVID-19 
5,077 (26.4%) patients in the primary HDU/ICU cohort died within the 30-day study period. 
Mean follow-up was 21.2 (SD 10.9) days in people with type 2 diabetes and 21.2 (SD 19.4) days in 
those without.  
 
Risk of mortality was consistently higher in people with type 2 diabetes in all analyses 
performed. The overall unadjusted cumulative incidence of 30-day mortality was higher in people 
with diabetes (34.7% [95%CI 33.1, 36.3]) than without diabetes (25.5% [95%CI 24.8, 26.2]) (Figure 
1). Mortality did not differ between people with diabetes recorded as missing/unknown diabetes status 
and those recorded as no diabetes (sFigure 1), supporting the assumption that missing coding 
represents the absence of diabetes. Unadjusted and adjusted hazard ratios showed higher mortality 
risk in people with diabetes, with a 23% increase in mortality risk observed in the fully adjusted 
model (Table 2). Full multivariable model outputs are provided in sTable 2. A 23% increase in 
mortality risk for diabetes was also observed in the propensity score matched analysis (Table 2).  
 
The mortality increase in people with type 2 diabetes was consistent in HDU cohort (type 2 
diabetes 30-day mortality 29.2% [95%CI 27.2, 31.1] versus 22.4% [95%CI 21.6, 23.2] without) and 
ICU cohort (30-day mortality 45.2% [42.4, 47.9] versus 36.3% [34.7, 37.8]) (sFigure 2, Table 2).  
 
The mortality risk for type 1 diabetes (n=203) was similar to that observed for type 2 
diabetes (adjusted hazard ratio (aHR) 0.98 [95%CI 0.75, 1.28], p=0.89), and in propensity score 
matched analysis the hazard ratio for type 1 diabetes was similar to that observed for matched 
controls without diabetes (aHR 1.25 [95%CI 0.86, 1.84], p=0.25) (sTable 3).  
 
Subgroup analysis suggests lower excess mortality risk associated with type 2 diabetes at 
older ages and in males compared to females 
Results of subgroup analyses for the primary outcome are shown in Figure 2. The association 
between type 2 diabetes and mortality was attenuated by age at hospital admission (age 18-49 aHR 
1.50 [95%CI 1.05;2.15]); age 50-64 aHR 1.29 [95%CI 1.10;1.51]; age 65 or greater aHR 1.18 [95%CI 
1.09;1.29], p=0.002 for age category:type 2 diabetes interaction), and there was a numerically lower 
excess mortality risk in males (aHR 1.15 [95%CI 1.05, 1.26]) than females (aHR 1.36 [95%CI 1.20, 
1.54], p=0.06 for sex:diabetes interaction). There was no evidence of a difference in the mortality 
associated with type 2 diabetes in subgroups defined by ethnicity (p=0.08), obesity (p=0.28), or by 
the presence or absence of other recorded comorbidity (p=0.41). There was no evidence of a temporal 
trend in the mortality associated with type 2 diabetes by calendar month (HR range 1.13-1.34 over 
March-July, sTable 3), or with adjustment for calendar week of hospital admission as an additional 
covariate (aHR for diabetes in the primary HDU/ICU cohort 1.21 [95%CI 1.13, 1.31], sTable 3). 
 
Sensitivity and multiple imputation analysis were consistent with the primary analysis 
 Results were consistent in all sensitivity analysis (sTable 3), including inclusion of only 
patients with a positive PCR swab result during admission, repeating the primary analysis with 
hospital added as a random effect, in the multiple imputation model, and, despite differences in 
clinical characteristics (sTable 4), including patients from all hospitals currently reporting to CHESS 




Our analysis of over 19,000 patients admitted to critical care over the entire first wave of 
COVID-19 in England demonstrates that type 2 diabetes is associated with around a 20% increase in 
mortality risk in people with severe COVID-19, independent of age, sex, ethnicity, obesity, and other 
major comorbidity. Risk is similar in both the HDU and ICU cohorts, despite the fact that in England 
these groups differed markedly with those admitted to ICU being younger, more commonly male, 
and more commonly of non-white ethnicity. Additional mortality risk appears similar in type 1 
diabetes compared to type 2 diabetes in this setting. 
 
Our national-level study provides evidence for a relatively small, but significant effect of 
diabetes on mortality risk in one of the largest samples of COVID-19 associated critical care 
admissions to date. The association between diabetes and COVID-19 mortality we observed is 
substantially smaller than those reported in studies conducted early in the pandemic.(11, 15) Notably, 
we extend previous contributions by evaluating both HDU and ICU admissions, which we 
demonstrate to be very different populations in terms of clinical characteristics. In England these 
differences between HDU and ICU populations likely result from individualised care strategies based 
on the patient’s best interests (which one UK-based centre implemented for 61% of 429 consecutive 
admissions),(26) rather than  sustained saturation of intensive care units for which there was limited 
evidence.(27) 
 
Given the large sample available, we were able to evaluate heterogeneity in mortality risk 
across subgroups defined by clinical features, and demonstrate that, in relative terms, the additional 
mortality risk associated with type 2 diabetes attenuates markedly in older people. In contrast to age, 
we found no evidence of heterogeneity in the mortality risk associated with diabetes in subgroups 
defined by the presence or absence of obesity, comorbidity, and ethnicity. There was weak evidence 
of heterogeneity by sex, with a numerically higher excess risk associated with diabetes in females 
than males (p=0.06), which may warrant future investigation. Importantly, we demonstrate a 
consistent strength of association between type 2 diabetes and mortality accounting for time trends 
in in-hospital mortality, and accounting for geographical clustering of hospitals, which is notable as 
recent studies have demonstrated substantial variation in COVID-19 specific critical care outcomes 
between institutions,(28) as well as a marked reduction in critical care mortality over the course of 
the pandemic.(29) 
 
Although direct evaluation of patient characteristics other than diabetes was not the focus of 
this study, the validity of our results is bolstered by demographic congruence with COVID-19 data 
from the UK’s Intensive Care National Audit and Research Centre (ICNARC),(30) where diabetes 
status is not available. Notably, both studies found similar effects for males (i.e. no difference), and 
people of Asian ethnicity (i.e. increased risk) in critical care settings (sTable 2). The exception is that 
we did not find an association between obesity and mortality, in contrast to ICNARC which reported 
an association of small magnitude for BMI, but without adjustment for diabetes or hyperglycaemia.  
 
Previous studies of other viral respiratory infections suggest findings of population-level 
studies should be extrapolated to the critical care setting with caution. For influenza, national surveys 
suggested increased influenza-specific mortality in people with diabetes,(31) however, large multi-
state European studies of ICU admissions for influenza showed no difference in mortality by diabetes 
status.(32) Our results, contrasted with the numerically much greater associations for diabetes 
reported in UK population based studies of COVID-19 mortality mirror this pattern of substantially 
reduced effect size.(7, 8) Such setting-specific differences likely reflect different frames of reference, 
wherein each study is capturing a different portion of a complicated pathway including the risk of 
being infected, then accessing services, subsequently being admitted, hospital treatments, and finally, 
dying in hospital.  
 
To our knowledge, CHESS is currently the largest critical care database of people with 
COVID-19 and coded diabetes status, providing near complete capture of severe COVID-19 cases 
across England during the first wave of the pandemic.(18) Our use of a methodologically robust 
modelling framework, with adjustment for potential confounders and multiple sensitivity analyses to 
evaluate the potential influence of missing data, lends additional credibility to our mortality estimates. 
Despite this, we cannot rule out unmeasured confounding as an explanation of our findings. Any 
interpretation of our results should be bounded by the knowledge that in the primary analysis we 
adjusted for variables along the causal pathway (e.g. cardiovascular comorbidities), which precludes 
any claim that associations relate to the causal role of type 2 diabetes in COVID-19 mortality.(33) 
However, the consistent size of association for type 2 diabetes observed across models with sequential 
adjustment of clinical features supports the interpretation that type 2 diabetes is an important 
prognostic factor for critical care patients.  
 
A limitation of the CHESS critical care dataset is the lack of validated case definitions for 
recorded comorbidities, and it is possible misclassification of diabetes status may have attenuated the 
mortality risk estimates observed in this study. A further important limitation is that the lack of 
standardised measurement of height and weight meant we had to adjust risk models for obesity status 
(BMI categorised </>30 kg/m2), rather than with more granular categorisation of BMI. A recent study 
of 6916 US patients diagnosed with COVID-19 suggest an independent J-shaped association between 
BMI category and mortality, with patients of BMI <18.5 kg/m2 and ≥40 kg/m2 at higher risk of 
mortality compared with those of normal BMI (18.5-24 kg/m2),(34) and an analysis of 1687 
hospitalised adults in New York observed a similar J-shaped pattern between BMI and mortality, 
although with overweight patients at lowest risk.(35) These analyses raise the possibility of residual 
confounding, due to the limited recording of BMI in CHESS, being a potential explanation of our 
findings. We lacked data to assess the impact of potentially modifiable diabetes specific risk factors 
in particular hyperglycaemia prior to, at, or during, hospital admission,(7, 14, 36-39) as well as 
possible modulatory effects of specific anti-hyperglycaemic medications.,(40-42) Clinical 
information on duration of diabetes and the presence of diabetes complications were similarly not 
available. Robustly evaluating the added value of such potential diabetes-specific prognostic factors 
is an important area for ongoing,(37, 39) and future, research to inform understanding of the 
mechanisms by which diabetes modifies outcome in severe COVID-19,(43) to establish which risk 
factors are most useful to identify which people with diabetes are most vulnerable to COVID-19,(44) 
and to inform individualised care strategies.(40)  
 
Conclusion 
Type 2 diabetes may be an independent prognostic factor for in-hospital survival in people 
with severe COVID-19 admitted to a critical care setting. The additional mortality risk associated 
with type 2 diabetes is attenuated by age. These results can help inform in-hospital decision-making 
on appropriate care escalation and treatment provision for people with type 2 diabetes and severe 
COVID-19.  
 
Funding: This study was supported by Diabetes UK.  
 
Role of the funding source: The funder had no role in the analysis, or reporting of results. 
 
Acknowledgements: JMD is supported by an Independent Fellowship funded by Research 
England’s Expanding Excellence in England (E3) fund. SJV, SD, and BAM are supported by The 
Alan Turing Institute (EPSRC grant EP/N510129/). RS receives a PhD stipend from EPRSC 
(EP/R513143/1). SJV is supported by the University of Warwick IAA funding. ATH is a NIHR 
Senior Investigator and a Wellcome Trust Senior Investigator (098395/Z/12/Z). JMD, NJT, KAP, 
ATH, and APM are supported by the NIHR Exeter Clinical Research Facility. We thank Public 
Health England for providing access to CHESS data to the Warwick Research Group and Matt 
Keeling for his support and establishing data access.  
 
Contributors: JMD, BAM, NJT, APM, and SV designed the study. JMD and RS drafted code on 
dummy data. SJV adapted and extended the code and executed on CHESS. JMD, BAM, APM, and 
SJV drafted the article. All authors provided support for the analysis and interpretation of results, 
critically revised the article, and approved the final article. JMD, BAM and SJV take responsibility 
for the integrity of the data and the accuracy of the data analysis. 
 
Declaration of interest: APM declares previous research funding from Eli Lilly and Company, 
Pfizer, and AstraZeneca. SJV declares funding from IQVIA. All other authors declare no competing 
interests. 
 
Data Sharing: Data cannot be shared publicly as it was collected by Public Health England (PHE) 
as part of their statutory responsibilities, which allows them to process patient confidential data 
without explicit patient consent. Data utilised in this study were made available through an 
agreement between the University of Warwick and PHE. Individual requests for access to CHESS 
data are considered directly by PHE (contact via covid19surv@phe.gov.uk).  
 
Ethics and governance: The study was reviewed and approved by the Warwick BSREC (BSREC 
119/19-20) and sponsorship is being provided by University of Warwick (SOC.28/19-20).  
 
Guarantors: The corresponding (BAM) and the senior author (SJV) had full access to all data and 
had final responsibility for the decision to submit for publication. Both guarantors affirm that 
manuscript is an honest, accurate, and transparent account of the study being reported; that no 
important aspects of the study have been omitted; and that any discrepancies from the study as 








1. COVID-19 situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-
2019/situation-reports (accessed May 20, 2020). 
2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and 
regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from 
the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 
2019;157:107843. 
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for 
mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 
(London, England). 2020;395(10229):1054-62. 
4. Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic Control and 
Risk of Infections Among People With Type 1 or Type 2 Diabetes in a Large Primary Care Cohort 
Study. Diabetes Care. 2018;41(10):2127-35. 
5. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. 
Diabetes Care. 2003;26(2):510-3. 
6. Magliano DJ, Harding JL, Cohen K, Huxley RR, Davis WA, Shaw JE. Excess Risk of 
Dying From Infectious Causes in Those With Type 1 and Type 2 Diabetes. Diabetes Care. 
2015;38(7):1274-80. 
7. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors 
associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6. 
8. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 
and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The 
Lancet Diabetes & Endocrinology. 
9. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular 
metabolic diseases on COVID-19 in China. Clinical research in cardiology : official journal of the 
German Cardiac Society. 2020;109(5):531-8. 
10. Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at 
higher risk of ICU admission and poor short-term outcome. Journal of Clinical Virology. 
2020;127:104354. 
11. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. 
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With 
COVID-19 in the New York City Area. Jama. 2020;323(20):2052-9. 
12. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 
20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation 
Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. 
13. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk 
Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, 
Retrospective Study. Diabetes Care. 2020:dc200598. 
14. Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of Blood Glucose 
Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell 
Metabolism. 2020;31(6):1068-77.e3. 
15. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and 
outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Research &amp; 
Care. 2020;8(1):e001343. 
16. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors 
Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, 
Italy. JAMA Internal Medicine. 2020. 
17. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors 
Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA 
Internal Medicine. 2020. 
18. Public_Health_England. COVID-19 Hospitalisation in England Surveillance System 
(CHESS) 2020 [Available from: https://www.england.nhs.uk/coronavirus/wp-
content/uploads/sites/52/2020/03/phe-letter-to-trusts-re-daily-covid-19-hospital-surveillance-11-
march-2020.pdf. 
19. Public Health England. COVID-19: investigation and initial clinical management of 
possible cases. 2020; published online Jan 10. https://www.gov.uk/government/publications/wuhan-
novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-
management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection (accessed May 26, 
2020). 
20. Groenwold RHH, White IR, Donders ART, Carpenter JR, Altman DG, Moons KGM. 
Missing covariate data in clinical research: when and when not to use the missing-indicator method 
for analysis. CMAJ. 2012;184(11):1265-9. 
21. Austin PC. A Tutorial on Multilevel Survival Analysis: Methods, Models and Applications. 
International Statistical Review. 2017;85(2):185-203. 
22. Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple 
imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 
2009;338:b2393. 
23. Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. In: Guyon I, 
Luxburg UV, Bengio S, et al., eds. Advances in Neural Information Processing Systems 30. Curran 
Associates, Inc., 2017: 4765–74. 
24. Spiegelhalter D. How old are you, really? Communicating chronic risk through ‘effective 
age’ of your body and organs. BMC Medical Informatics and Decision Making. 2016;16(1):104. 
25. Development Core Team RR. R: A language and environment for statistical computing. 
2011. 
26. Vlachos S, Wong A, Metaxa V, Canestrini S, Lopez Soto C, Periselneris J, et al. Hospital 
mortality and resource implications of hospitalisation with COVID-19 in London, UK: a 
prospective cohort study. medRxiv. 2020:2020.07.16.20155069. 
27. Mateen BA, Wilde H, Dennis Jm, Duncan A, Thomas NJM, McGovern AP, et al. A 
geotemporal survey of hospital bed saturation across England during the first wave of the COVID-
19 Pandemic. medRxiv. 2020:2020.06.24.20139048. 
28. Qian Z, Alaa AM, van der Schaar M, Ercole A. Between-centre differences for COVID-19 
ICU mortality from early data in England. Intensive Care Medicine. 2020. 
29. Dennis J, McGovern A, Vollmer S, Mateen BA. Improving COVID-19 critical care 
mortality over time in England: A national cohort study, March to June 2020. medRxiv. 
2020:2020.07.30.20165134. 
30. Intensive Care National Audit & Research Centre (ICNARC). ICNARC report on COVID-
19 in critical care 31 July 2020. https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports (accessed 
Aug 15, 2020). 
31. Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality 
associated with pneumonia and influenza among non-Hispanic black and white US adults. 
American journal of public health. 1999;89(11):1715-21. 
32. Adlhoch C, Gomes Dias J, Bonmarin I, Hubert B, Larrauri A, Oliva Domínguez JA, et al. 
Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, 
European Union 2009-2017. Open forum infectious diseases. 2019;6(11):ofz462. 
33. Huitfeldt A. Is caviar a risk factor for being a millionaire? BMJ. 2016;355:i6536. 
34. Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and Mortality 
Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. 
Annals of internal medicine. 2020:M20-3742. 
35. Goyal P, Ringel JB, Rajan M, Choi JJ, Pinheiro LC, Li HA, et al. Obesity and COVID-19 in 
New York City: A Retrospective Cohort Study. Annals of Internal Medicine. 2020. 
36. Riddle MC. Diabetes and COVID-19: Moving From News to Knowledge and a Glucose 
Hypothesis. Diabetes Care. 2020:dci200045. 
37. Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic 
characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. 
Diabetologia. 2020;63(8):1500-15. 
38. Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, et al. Hyperglycemia 
at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for 
COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020:dc201380. 
39. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for 
COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-
based cohort study. The Lancet Diabetes & Endocrinology. 
40. Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized 
for COVID-19: Findings from the CORONADO study and other recent reports. Diabetes & 
Metabolism. 2020. 
41. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 
in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & 
Endocrinology. 2020;8(9):782-92. 
42. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, et al. Clinical Characteristics and 
Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering 
Medication. Diabetes Care. 2020:dc200660. 
43. Mauvais-Jarvis F. Aging, Male Sex, Obesity, and Metabolic Inflammation Create the 
Perfect Storm for COVID-19. Diabetes. 2020;69(9):1857-63. 
44. Riddle MC, Buse JB, Franks PW, Knowler WC, Ratner RE, Selvin E, et al. COVID-19 in 




Table 1: Recorded characteristics of HDU/ICU cohort, by recorded type 2 diabetes status 
 No type 2 diabetes (n=15,732) Type 2  diabetes (n=3,524) 
Age (years) 66 (17.4)  67 (14.1) 
Age Group 
18-24  164 ( 1.0)  8 ( 0.2)  
25-34  612 ( 3.9)  40 ( 1.1)  
35-44  1,010 ( 6.4)  142 ( 4.0)  
45-54  2,039 (13.0)  429 (12.2)  
55-64  2,814 (17.9)  848 (24.1)  
65-74  2,978 (18.9)  872 (24.7)  
75-84  3,334 (21.2)  718 (20.4)  
85+  2,781 (17.7)  467 (13.3) 
Sex 
Female  6,440 (40.9)  1,243 (35.3)  
Male  9,292 (59.1)  2,281 (64.7)  
Ethnicity* 
White  9,624 (76.5)  1,815 (58.5)  
Asian  1,356 (10.8)  680 (21.9)  
Black  737 ( 5.9)  360 (11.6)  
Mixed  163 ( 1.3)  48 ( 1.5)  
Other  694 ( 5.5)  201 ( 6.5)  
Obesity** 
Non-obese  6,034 (68.6)  1,509 (54.9)  
Obese  2,764 (31.4)  1,240 (45.1)  
Comorbidity 
Any comorbidity 6228 (39.6) 2945 (83.6) 
Chronic respiratory disease  1,250 ( 7.9)  423 (12.0)  
Asthma  1,200 ( 7.6)  428 (12.1)  
Hypertension  3,439 (21.9)  2,218 (62.9)  
Chronic heart disease  1,828 (11.6)  834 (23.7)  
Chronic renal disease  996 ( 6.3)  831 (23.6)  
Chronic liver disease  252 ( 1.6)  138 ( 3.9)  
Chronic neurological disease  1,098 ( 7.0)  310 ( 8.8)  
Immunosuppressive disease  374 ( 2.4)  94 ( 2.7) 
 
*Ethnicity not recorded for 3,578 patients. **Obesity not recorded for 7,709 patients.  
Table 2: Hazard ratios for diabetes for the primary outcome of 30 day in-hospital mortality 
for people with type 2 diabetes admitted to critical care with COVID-19. Age fitted as a 
restricted cubic spline with 3 knots in all models. 
Adjustment Cohort 1: All patients 
(n=19,256) 
Cohort 2: HDU only 
patients (n=13,809) 
Cohort 3: ICU patients 
(n=5,447) 
Unadjusted 1.44 (1.35, 1.54), 
p<0.001 
1.38 (1.26, 1.51), 
p<0.001 
1.34 (1.22, 1.48), 
p<0.001 
Age 1.42 (1.33, 1.51), 
p<0.001 
1.31 (1.20, 1.44), 
p<0.001 
1.28 (1.16, 1.41), 
p<0.001 
Age and sex 1.40 (1.31, 1.49), 
p<0.001 
1.30 (1.19, 1.42), 
p<0.001 
1.28 (1.16, 1.41), 
p<0.001 
Age, sex, ethnicity 1.36 (1.27, 1.45), 
p<0.001 
1.29 (1.18, 1.41), 
p<0.001 
1.23 (1.11, 1.36), 
p<0.001 
Age, sex, ethnicity, obesity 1.32 (1.23, 1.41), 
p<0.001 
1.27 (1.16, 1.39), 
p<0.001 
1.29 (1.17, 1.43), 
p<0.001 
Full covariate set adjusted model 
(Age, sex, ethnicity, obesity, 
comorbidity*) 
1.23 (1.14, 1.32), 
p<0.001 
1.19 (1.08, 1.31), 
p<0.001 
1.24 (1.11, 1.38), 
p<0.001 
Propensity score matched model, 
adjusted full covariate set 
1.25 (1.14, 1.36), 
p<0.001 [n=3,289 with 
diabetes matched] 
1.17 (1.04, 1.32), 
p=0.01 [n=2,007 with 
diabetes matched] 
1.19 (1.05, 1.35), 
p=0.009 [n=1,244 with 
diabetes matched] 
Competing risk model, adjusted full 
covariate set (Fine-Gray)** 
1.27 (1.18, 1.36), 
p<0.001 
1.24 (1.13, 1.36), 
p<0.001 
1.24 (1.12, 1.38),p<0.001 
*Chronic respiratory disease, Asthma, Chronic heart disease, Hypertension, Immunosuppression, Chronic neurological disease, 
Chronic renal disease, Chronic liver disease. 





Figure 1: Kaplan-Meier plots for in-hospital COVID-19 death in 19,256 patients admitted to 
critical care (HDU or ICU) in CHESS by time since hospital admission. Plot shows the 
proportion of individuals at risk who were still alive at regular intervals up to 30 days from 
admission, stratified by the presence of type 2 diabetes. People discharged from hospital prior to 30 
days were assumed to survive to 30 days and are included in the number at-risk until 30 days, in 




Figure 2: Major subgroup analysis of the primary outcome of 30 day in-hospital mortality.  
 
 
Legend: Hazard ratios represent the mortality risk associated with the presence of type 2 diabetes in each 
subgroup. Bars represent 95% confidence intervals. *Hazard ratios (95% CI) for other subgroups: mixed 
ethnicity 1.91 (1.03, 3.56), other ethnicity 0.96 (0.67, 1.39), missing ethnicity 1.34 (1.11, 1.62), missing 
obesity 1.28 (1.08, 1.46). 
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sTable 1: Recorded characteristics of study cohorts.  
 
 HDU/ICU cohort 
(n=19,256) 
HDU only cohort 
(n=13,809) 
ICU cohort  
(n=5,447) 
Age in years (Mean [SD]) 67 (16.88)  70 (17.21)  58 (12.66)  
Age Group 
18-24  172 (0.9)  134 (1.0)  38 (0.7) 
25-34  652 (3.4)  446 (3.2)  206 (3.8) 
35-44  1,152 (6.0)  695 (5.0)  457 (8.4) 
45-54  2,468 (12.8)  1,331 (9.6)  1,137 (20.9) 
55-64  3,662 (19.0)  1,900 (13.8)  1,762 (32.3) 
65-74  3,850 (20.0)  2,550 (18.5)  1,300 (23.9) 
75-84  4,052 (21.0)  3,551 (25.7)  501 ( 9.2) 
85+  3,248 (16.9)  3,202 (23.2)  46 ( 0.8)  
Sex 
Female  7,683 (39.9)  6,084 (44.1)  1,599 (29.4)  
Male  11,573 (60.1)  7,725 (55.9)  3,848 (70.6)  
Ethnicity 
White  11,439 (73.0)  8,413 (76.9)  3,026 (63.9)  
Asian  2,036 (13.0)  1,204 (11.0)  832 (17.6)  
Black  1,097 ( 7.0)  727 (6.6)  370 (7.8)  
Mixed  211 (1.3)  72 (0.7)  139 (2.9)  
Other  895 (5.7)  523 (4.8)  372 (7.8)  
Obesity 
Non-obese  7,543 (65.3)  5,467 (75.8)  2,076 (47.9)  
Obese  4,004 (34.7)  1,742 (24.2)  2,262 (52.1)  
Comorbidity 
Type 2 diabetes  3,524 (18.3)  2,139 (15.5)  1,385 (25.4)  
Chronic respiratory disease  1,673 (8.7)  1,166 (8.4)  507 (9.3)  
Asthma  1,628 (8.5)  929 (6.7)  699 (12.8)  
Hypertension  5,657 (29.4)  3,602 (26.1)  2,055 (37.7)  
Chronic heart disease  2,662 (13.8)  2,034 (14.7)  628 (11.5)  
Chronic renal disease  1,827 (9.5)  1,426 (10.3)  401 (7.4)  
Chronic liver disease  390 (2.0)  244 (1.8)  146 (2.7)  
Chronic neurological disease  1,408 (7.3)  1,174 (8.5)  234 (4.3)  
Immunosuppressive disease  468 (2.4)  274 (2.0)  194 (3.6) 
Time in hospital 
Days from hospital to ICU admission 





SFigure 1: Kaplan-Meier plots for in-hospital COVID-19 death in 19,256 patients admitted to critical care (HDU 
or ICU) in CHESS by time since hospital admission, with type 2 diabetes status coded as Yes, No, and Not 
recorded. Plots show the proportion of individuals at risk who were still alive at regular intervals up to 30 days from 
admission. People discharged from hospital prior to 30 days were assumed to survive to 30 days and are included in the 
number at-risk until 30 days, in keeping with the standard practice for time-to-event modelling in analysis of critical 





SFigure 2: Kaplan-Meier plots for in-hospital COVID-19 death over time, by diabetes status for: 
a) HDU only cohort, n=13,809)  
 






sTable 2: Hazard ratios for full covariate set in multivariable analysis of the primary outcome of 30 day all-cause 
in-hospital mortality for each study cohort. Data in brackets are 95% confidence intervals. 
 
 HDU/ICU cohort 
(n=19,256) 
HDU only cohort 
(n=13,809) 
ICU cohort  
(n=5,447) 
Type 2 diabetes 
No type 2 diabetes  1.00 (ref)  1.00 (ref)  1.00 (ref)  
Type 2 diabetes  1.23 (1.14;1.32), p<0.001  1.19 (1.08;1.31), p<0.001  1.24 (1.11;1.38), p<0.001  
Age 
Age spline  1.06 (1.06;1.07), p<0.001  1.10 (1.09;1.11), p<0.001  1.04 (1.03;1.05), p<0.001   
Age spline'  0.97 (0.96;0.98), p<0.001  0.96 (0.95;0.97), p<0.001   1.00 (0.99;1.01), p=0.699  
Sex 
Female 1·00 (ref) 1·00 (ref) 1·00 (ref) 
Male 1.33 (1.25;1.41), p<0.001  1.30 (1.21;1.39), p<0.001   1.08 (0.98;1.20), p=0.121  
Ethnicity* 
White  1.00 (ref)  1.00 (ref)  1.00 (ref)  
Asian  1.32 (1.20;1.46), p<0.001   1.24 (1.07;1.45), p=0.005  1.27 (1.11;1.44), p<0.001  
Black  1.19 (1.04;1.35), p=0.010  1.19 (0.99;1.44), p=0.065  1.33 (1.11;1.59), p=0.002  
Mixed  1.74 (1.34;2.25), p=0.000  1.52 (0.90;2.58), p=0.119  1.24 (0.92;1.67), p=0.157  
Other  1.00 (0.85;1.17), p=0.964  0.83 (0.63;1.08), p=0.165  0.99 (0.81;1.20), p=0.887  
Missing  1.10 (1.01;1.18), p=0.020  1.16 (1.06;1.27), p=0.001  1.03 (0.90;1.19), p=0.645  
Obesity** 
Non-obese (BMI<30) 1.00 (ref)  1.00 (ref)  1.00 (ref)  
Obese (BMI≥30) 1.06 (0.99;1.15), p=0.113  0.84 (0.74;0.95), p=0.007  0.95 (0.86;1.06), p=0.393 
Missing 0.94 (0.88;1.01), p=0.089  0.89 (0.82;0.97), p=0.005  1.51 (1.35;1.70), p<0.001  
Comorbidity (versus No/Missing) 
Chronic respiratory disease  1.29 (1.18;1.41), p<0.001  1.35 (1.21;1.51), p<0.001  1.11 (0.96;1.28), p=0.175  
Asthma  1.02 (0.92;1.13), p=0.755  0.99 (0.85;1.14), p=0.862  0.92 (0.79;1.06), p=0.253  
Hypertension  1.04 (0.97;1.11), p=0.237  0.91 (0.83;0.99), p=0.024  1.01 (0.91;1.12), p=0.846  
Chronic heart disease  1.11 (1.03;1.20), p=0.009  1.11 (1.01;1.22), p=0.026  1.10 (0.97;1.26), p=0.146  
Chronic renal disease  1.17 (1.07;1.27), p<0.001  1.24 (1.11;1.37), p<0.001  1.29 (1.11;1.50), p=0.001  
Chronic liver disease  0.99 (0.81;1.21), p=0.924  1.21 (0.93;1.58), p=0.162  0.91 (0.67;1.23), p=0.540  
Chronic neurological disease  1.12 (1.02;1.23), p=0.022  1.20 (1.07;1.33), p=0.001  1.13 (0.91;1.39), p=0.276  
Immunosuppressive disease  1.23 (1.05;1.44), p=0.009  1.20 (0.97;1.49), p=0.095  1.01 (0.80;1.27), p=0.938 
Time in hospital 
Days from hospital to ICU 
admission (per day increase) NA  NA  1.00 (0.99;1.01), p=0.722  
*Ethnicity not recorded for HDU/ICU 3,578 patients; HDU 2,870; ICU 708. **Obesity not recorded for HDU/ICU 7,709 patients; 






sTable 3: Hazard ratios for additional subgroup and sensitivity analysis. Data in brackets are 95% confidence 
intervals. 
 
Subgroup and sensitivity 
analysis. All adjusted for the full 
covariate set. 
HDU/ICU cohort HDU only cohort  ICU cohort  
 
Admitted to hospital in March 
2020 (All n=5606, HDU n=3,725, 
ICU n=1881) 
1.34 (1.18, 1.51), 
p<0.001 
1.39 (1.18, 1.64), 
p<0.001 
1.30 (1.09, 1.54), 
p=0·003 
Admitted to hospital in April 2020 
(All n=9440, HDU n=6,666, ICU 
n=2774) 
1.13 (1.02, 1.26),  
p=0.02 
1.05 (0.92, 1.21), p=0.47 1.19 (1.02, 1.39), 
p=0.03 
Admitted to hospital in May-July 
2020 (All n=4210, HDU n=3418, 
ICU n=792) 
1.24 (1.01, 1.52),  
p=0.04 
1.24 (0.96, 1.60), p=0.10 1.19 (0.84, 1.69), 
p=0.34 
Calendar week of hospital 
admission added as an addition 
covariate (All n=19,256, HDU 
n=13,809, ICU n=5,447) 
1.21 (1.13, 1.31), 
p<0.001 
1.18 (1.07, 1.30), 
p<0.001 
1.22 (1.10, 1.36), 
p<0.001 
Exclude transferred patients and 
patient who remain in hospital (All 
n=17,044, HDU n=13,033, ICU 
n=4,483) 
1.22 (1.14, 1.31), 
p<0.001 
1.17 (1·06, 1·29), 
p=0·002 
1·24 (1.11, 1.38), 
p<0·001 
Include only patients with PCR 
swab positive result during 
admission (All n=17,606, HDU 
n=12,550, ICU n=5056) 
1.23 (1.14, 1.32), 
p<0.001 
1.22 (1.11, 1.35), 
p<0.001 
1.18 (1.06, 1.32), 
p=0.004 
NHS Trust as additional random 
effect (All n=19,256, HDU 
n=13,809, ICU n=5,447) 
1·19 (1·11, 1·29), 
p<0·001 
1.20 (1.09, 1.32), 
p<0.001 
1.18 (1.06, 1.32), 
p=0·003 
Multiple imputation model (All 
n=19,256, HDU n=13,809, ICU 
n=5,447) 
1.25 (1.15, 1.36), 
p<0.001 
1.16 (1.03, 1.31),  
p=0.02 
1.31 (1.16, 1.49), 
P<0.001 
Include patients from all hospitals, 
assuming non-coded comorbidity 
represents the absence of a 
comorbidity (All n=21452 , HDU 
n=15,637, ICU n=5,815) 
1.26 (1.17, 1.35), 
p<0·001 
1.24 (1.13, 1.36), 
p<0·001 
1.25 (1.12, 1.39), 
p<0·001 
Include patients only from 
hospitals with <25% missing 
comorbidity coding (All n=13,995, 
HDU n=8,8981, ICU n=4,482) 
1·25 (1·16, 1·35), 
p<0·001 
1·25 (1·12, 1·39), 
p<0·001 
1·27 (1·13, 1·42), 
p<0·001 
sTable 4: Recorded characteristics of patients in hospitals included and excluded from study cohorts. Data are N 




 Hospitals excluded  (hospital n= 15,  
patient n=1,993) 
Hospitals included  
(hospital n=91,  
patient n=19,256) 
Age in years (Mean [SD]) 70 (16.26) 67 (16.88) 
Age Group 
18-24 14 (0.7) 172 (0.9)  
25-34 39 (2.0) 652 (3.4)  
35-44 91 (4.6) 1,152 (6.0)  
45-54 235 (11.8) 2,468 (12.8)  
55-64 282 (14.1) 3,662 (19.0)  
65-74 398 (20.0) 3,850 (20.0)  
75-84 509 (25.5) 4,052 (21.0)  
85+ 425 (21.3) 3,248 (16.9)  
Sex 
Female 827 (41.5) 7,683 (39.9)  
Male 1,166 (58.5) 11,573 (60.1)  
Ethnicity 
White 735 (36.9) 11,439 (59.4)  
Asian 80 (4.0) 2,036 (10.6)  
Black 11 (0.6) 1,097 (5.7)  
Mixed 7 (0.4) 211 (1.1)  
Other 14 (0.7) 895 (4.6)  
Not recorded 1,146 (57.5) 3,578 (18.5) 
Obesity 
Non-obese 61 (3.1) 7,543 (39.1)  
Obese 36 (1.8) 4,004 (20.8)  
Not recorded 1,896 (95.1) 7,709 (40.0) 
Comorbidity (recorded yes) 
Diabetes 80 (4.0) 3,524 (18.3)  
Chronic respiratory disease 66 (3.3) 1,673 (8.7)  
Asthma 27 (1.4) 1,628 (8.5)  
Hypertension 123 (6.2) 5,657 (29.4)  
Chronic heart disease 70 (3.5) 2,662 (13.8)  
Chronic renal disease 38 (1.9) 1,827 (9.5)  
Chronic liver disease 3 ( 0.2) 390 (2.0)  
Chronic neurological disease 40 (2.0) 1,408 (7.3)  
Immunosuppressive disease 15 (0.8) 468 (2.4)  
Time in hospital 
Admitted to ICU 294 (14.8) 5,447 (28.2) 
 
 
